Literature DB >> 10642175

Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.

K List1, O N Jensen, T H Bugge, L R Lund, M Ploug, K Danø, N Behrendt.   

Abstract

The plasminogen activation (PA) system is involved in the degradation of fibrin and various extracellular matrix proteins, taking part in a number of physiological and pathological tissue remodeling processes including cancer invasion. This system is organized as a classical proteolytic cascade, and as for other cascade systems, understanding the physiological initiation mechanism is of central importance. The attempts to identify initiation routes for activation of the proform of the key enzyme urokinase-type plasminogen activator (pro-uPA) in vivo have been hampered by the strong activator potency of the plasmin, that is generated during the progress of the cascade. Using gene-targeted mice deficient in plasminogen (Plg -/- mice) [Bugge, T. H., Flick, M. J., Daugherty, C. C., and Degen, J. L. (1995) Genes Dev. 9, 794-807], we have now demonstrated and identified a component capable of initiating the cascade by activating pro-uPA. The urine from Plg -/- mice contained active two-chain uPA as well as a proteinase capable of activating exogenously added pro-uPA. The active component was purified and identified by mass spectrometry-based peptide mapping as mouse glandular kallikrein mGK-6 (true tissue kallikrein). The pro-uPA converting activity of the mGK-6 enzyme, as well as its ability to cleave a synthetic substrate for glandular kallikrein, was inhibited by the serine proteinase inhibitor leupeptin but not by other serine proteinase inhibitors such as aprotinin, antithrombin III, or alpha(1)-antitrypsin. We suggest that mouse glandular kallikrein mGK-6 is an activator of pro-uPA in the mouse urinary tract in vivo. Since this kallikrein is expressed in a number of tissues and also occurs in plasma, it can also be considered a candidate for a physiological pro-uPA activator in other locations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10642175     DOI: 10.1021/bi991701f

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Authors:  Kenneth A Botkjaer; Sarah Fogh; Erin C Bekes; Zhuo Chen; Grant E Blouse; Janni M Jensen; Kim K Mortensen; Mingdong Huang; Elena Deryugina; James P Quigley; Paul J Declerck; Peter A Andreasen
Journal:  Biochem J       Date:  2011-08-15       Impact factor: 3.857

2.  Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.

Authors:  Sergei Zaitsev; Dirk Spitzer; Juan-Carlos Murciano; Bi-Sen Ding; Samira Tliba; M Anna Kowalska; Oscar A Marcos-Contreras; Alice Kuo; Victoria Stepanova; John P Atkinson; Mortimer Poncz; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2010-04-21       Impact factor: 22.113

Review 3.  Functional intersection of the kallikrein-related peptidases (KLKs) and thrombostasis axis.

Authors:  Michael Blaber; Hyesook Yoon; Maria A Juliano; Isobel A Scarisbrick; Sachiko I Blaber
Journal:  Biol Chem       Date:  2010-04       Impact factor: 3.915

4.  The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.

Authors:  Niels Behrendt; Karin List; Peter A Andreasen; Keld Danø
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

5.  A novel mode of intervention with serine protease activity: targeting zymogen activation.

Authors:  Grant E Blouse; Kenneth A Bøtkjaer; Elena Deryugina; Aleksandra A Byszuk; Janni M Jensen; Kim K Mortensen; James P Quigley; Peter A Andreasen
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

6.  Intracellular localization of protein C inhibitor (PCI) and urinary plasminogen activator in renal tubular epithelial cells from humans and human PCI gene transgenic mice.

Authors:  Zhenhu Song; Ning Ma; Tatsuya Hayashi; Esteban C Gabazza; Yoshiki Sugimura; Koji Suzuki
Journal:  Histochem Cell Biol       Date:  2007-10       Impact factor: 4.304

7.  Potent antitumor activity of a urokinase-activated engineered anthrax toxin.

Authors:  Shihui Liu; Hannah Aaronson; David J Mitola; Stephen H Leppla; Thomas H Bugge
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-13       Impact factor: 11.205

8.  HATL5: a cell surface serine protease differentially expressed in epithelial cancers.

Authors:  Gregory S Miller; Gina L Zoratti; Andrew S Murray; Christopher Bergum; Lauren M Tanabe; Karin List
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

9.  The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.

Authors:  Christoffer Fagernæs Nielsen; Sander Maarten van Putten; Ida Katrine Lund; Maria Carlsén Melander; Kirstine Sandal Nørregaard; Henrik Jessen Jürgensen; Kristian Reckzeh; Kristine Rothaus Christensen; Signe Ziir Ingvarsen; Henrik Gårdsvoll; Kamilla Ellermann Jensen; Petra Hamerlik; Lars Henning Engelholm; Niels Behrendt
Journal:  Oncotarget       Date:  2017-07-04

10.  Immune regulation by fibroblasts in tissue injury depends on uPARAP-mediated uptake of collectins.

Authors:  Henrik J Jürgensen; Kirstine S Nørregaard; Megan M Sibree; Eric Santoni-Rugiu; Daniel H Madsen; Katharina Wassilew; Dorrit Krustrup; Peter Garred; Thomas H Bugge; Lars H Engelholm; Niels Behrendt
Journal:  J Cell Biol       Date:  2018-10-26       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.